AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15682973 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal BCG vaccination
Number of subjects: 0
Study 16084808 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait trainer exercise with functional electric stimulation (GTstim)
Number of subjects: 45
Study 16084808 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait trainer exercise without stimulation (GT)
Number of subjects: 45
Study 16084808 — intervention group
Group type: COMPARATOR
Intervention: Walking overground (WALK)
Number of subjects: 45
Study 16084808 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (GTstim, GT, WALK)
Number of subjects: 45
Study 10485530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac ophthalmic drops 0.5% prescribed four times a day for at least 3 months
Number of subjects: 9
Study 8934482 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (2 ml containing 40 mg of triamcinolone acetonide + 4 ml of 1% lidocaine without epinephrine)
Number of subjects: 40
Study 8934482 — intervention group
Group type: COMPARATOR
Intervention: Control (6 ml of 1% lidocaine without epinephrine)
Number of subjects: 40
Study 8934482 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 40
Study 8934482 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 1882910 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 21
Study 1882910 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole
Number of subjects: 21
Study 1882910 — intervention group
Group type: COMPARATOR
Intervention: Maalox
Number of subjects: 21
Study 6352169 — intervention group
Group type: EXPERIMENTAL
Intervention: Antabuse (50 to 200 mg daily for 6 weeks)
Number of subjects: 24
Study 6352169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6352169 — intervention group
Group type: EXPERIMENTAL
Intervention: Antabuse
Number of subjects: 24
Study 30657226 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude diary
Number of subjects: 201
Study 30657226 — intervention group
Group type: COMPARATOR
Intervention: Food diary
Number of subjects: 201
Study 29045995 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte solution (CES)
Number of subjects: 7
Study 26548549 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual orphan care plus mentoring, financial education, and matched savings accounts
Number of subjects: 346
Study 26548549 — intervention group
Group type: COMPARATOR
Intervention: Usual orphan care plus mentoring (Control)
Number of subjects: 346
Study 24735962 — intervention group
Group type: EXPERIMENTAL
Intervention: FC plus subcutaneous alemtuzumab 30 mg on day 1 (FCA)
Number of subjects: 272
Study 24735962 — intervention group
Group type: COMPARATOR
Intervention: FC (control)
Number of subjects: 272
Study 22987879 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention (dietary and physical/sedentary activities education, behavioral modification)
Number of subjects: 96
Study 22987879 — intervention group
Group type: COMPARATOR
Intervention: Information control (IC)
Number of subjects: 96
Study 19488646 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150mg three times a week for six months)
Number of subjects: 24
Study 19488646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19488646 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 24
Study 17321952 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 fatty acid supplementation
Number of subjects: 0
Study 17321952 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 15279439 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of place and task (Experiment 1)
Number of subjects: 3
Study 15279439 — intervention group
Group type: EXPERIMENTAL
Intervention: Place alone (Experiment 2)
Number of subjects: 3
Study 15279439 — intervention group
Group type: EXPERIMENTAL
Intervention: Task alone (Experiment 3)
Number of subjects: 3
Study 11575484 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Decision Support Aid (DSA)
Number of subjects: 56
Study 11575484 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Decision Support Aid (DSA)
Number of subjects: 56
Study 11575484 — intervention group
Group type: COMPARATOR
Intervention: No Decision Support Aid (DSA)
Number of subjects: 56
Study 9696518 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightbox treatment with 1500-2500 lux white light for 2 h in the morning for 6 days (n=34)
Number of subjects: 61
Study 9696518 — intervention group
Group type: EXPERIMENTAL
Intervention: Dawn simulation treatment in their homes, with 60 or 90 min of light augmentation time to 100-300 lux for 2 weeks (n=27)
Number of subjects: 61
Study 8024920 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fentanyl anaesthesia
Number of subjects: 12
Study 8024920 — intervention group
Group type: COMPARATOR
Intervention: Low-dose fentanyl anaesthesia
Number of subjects: 12
Study 29690959 — intervention group
Group type: EXPERIMENTAL
Intervention: Obtura II gutta‐percha with AH plus sealer
Number of subjects: 70
Study 29690959 — intervention group
Group type: COMPARATOR
Intervention: Obtura II gutta‐percha with Sealapex sealer
Number of subjects: 70
Study 29158726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral glycinate complexes + 2 CENs (daily dose: 36 mg iron, 15 mg zinc, 2 mg copper, 2 g carnitine, 400 mg phosphatidylserine)
Number of subjects: 31
Study 29158726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral glycinate complexes + 2 CENs (1 g carnitine)
Number of subjects: 31
Study 29158726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral glycinate complexes + 2 CENs
Number of subjects: 31
Study 29158726 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic minerals + CENs
Number of subjects: 31
Study 29158726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 26189886 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND) served for lunch during the intervention period
Number of subjects: 834
Study 26189886 — intervention group
Group type: COMPARATOR
Intervention: Control group (packed lunch)
Number of subjects: 834
Study 26189886 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 834
Study 24179297 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognitive Therapy (SCT)
Number of subjects: 206
Study 24179297 — intervention group
Group type: COMPARATOR
Intervention: Social Interaction (SI)
Number of subjects: 206
Study 21173173 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg per os once daily for 5 days
Number of subjects: 90
Study 21173173 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin 300 mg per os four times daily for 5 days
Number of subjects: 90
Study 21173173 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 90
Study 18837976 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercises
Number of subjects: 20
Study 18837976 — intervention group
Group type: EXPERIMENTAL
Intervention: Body scan
Number of subjects: 20
Study 18837976 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 20
Study 16448896 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 21
Study 16448896 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg)
Number of subjects: 21
Study 12883365 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL172 + low-dose IL-2
Number of subjects: 32
Study 12883365 — intervention group
Group type: COMPARATOR
Intervention: SRL172 alone
Number of subjects: 32
Study 10701731 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine suspension (16 g in 240 ml normal saline)
Number of subjects: 17
Study 10701731 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 17
Study 9412131 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered microcrystalline cellulose dosed 5 g/day for three months
Number of subjects: 50
Study 9412131 — intervention group
Group type: COMPARATOR
Intervention: Powdered corn starch
Number of subjects: 50
Study 8242128 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotrophin-releasing hormone (CRF) test (1 μg/kg body weight)
Number of subjects: 22
Study 8242128 — intervention group
Group type: COMPARATOR
Intervention: Control saline study
Number of subjects: 22
Study 3519041 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose alizapride (4 mg/kg X five doses)
Number of subjects: 62
Study 3519041 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide (2 mg/kg X five doses)
Number of subjects: 62
Study 29494489 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharide/polydextrose formula (PF)
Number of subjects: 201
Study 29494489 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 201
Study 29494489 — intervention group
Group type: COMPARATOR
Intervention: Exclusive breastfeeding (BF)
Number of subjects: 201
Study 26315810 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed ticagrelor 180 mg (2 tablets, semi-upright position)
Number of subjects: 20
Study 26315810 — intervention group
Group type: COMPARATOR
Intervention: Integral ticagrelor 180 mg (2 tablets, supine position)
Number of subjects: 20
Study 24560995 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 55
Study 24560995 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized LASIK
Number of subjects: 55
Study 21221678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric-C
Number of subjects: 49
Study 21221678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric-EC
Number of subjects: 49
Study 21221678 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradia-DP
Number of subjects: 49
Study 20070961 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (800 microg at the time of peritoneal incision)
Number of subjects: 200
Study 20070961 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin infusion (after delivery of the neonate)
Number of subjects: 200
Study 18788841 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.5 mg or 1.0 mg)
Number of subjects: 0
Study 18788841 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.075 mg/kg)
Number of subjects: 0
Study 16279150 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials in 2002
Number of subjects: 494
Study 12481161 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Number of subjects: 127
Study 12481161 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 127
Study 12481161 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg
Number of subjects: 127
Study 10068575 — intervention group
Group type: COMPARATOR
Intervention: Amprenavir (1200 mg) alone
Number of subjects: 92
Study 10068575 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir with zidovudine (300 mg) plus lamivudine (150 mg)
Number of subjects: 92
Study 10068575 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (Amprenavir, zidovudine, and lamivudine)
Number of subjects: 92
Study 7569287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 10
Study 2077509 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 22
Study 2077509 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 22
Study 2077509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6770760 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (30-60 mg/kg per day)
Number of subjects: 64
Study 6770760 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone (3-6 mg/kg per day)
Number of subjects: 64
Study 6770760 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 64
Study 30607983 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation applied to the quadriceps muscles (n=23)
Number of subjects: 45
Study 30607983 — intervention group
Group type: COMPARATOR
Intervention: Control group received electrical stimulation on the tibialis anterior muscle (n=22)
Number of subjects: 45
Study 30511796 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAC videolaryngoscope
Number of subjects: 80
Study 30511796 — intervention group
Group type: COMPARATOR
Intervention: Truview Picture Capture Device
Number of subjects: 80
Study 26876926 — intervention group
Group type: EXPERIMENTAL
Intervention: BLA activation during successful encoding of negative scenes in PTSD
Number of subjects: 22
Study 26876926 — intervention group
Group type: COMPARATOR
Intervention: BLA activation during successful encoding of negative scenes in TEC
Number of subjects: 22
Study 26876926 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-related activity in the BLA
Number of subjects: 22
Study 24026542 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 12
Study 24026542 — intervention group
Group type: COMPARATOR
Intervention: Control (usual diabetes regimen)
Number of subjects: 12
Study 22875559 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative care
Number of subjects: 11
Study 22875559 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 11
Study 21121833 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC (docetaxel, doxorubicin, and cyclophosphamide)
Number of subjects: 1060
Study 21121833 — intervention group
Group type: COMPARATOR
Intervention: FAC (fluorouracil, doxorubicin, and cyclophosphamide)
Number of subjects: 1060
Study 21121833 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC
Number of subjects: 1060
Study 21121833 — intervention group
Group type: COMPARATOR
Intervention: FAC
Number of subjects: 1060
Study 17970229 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) for sensitization to wheat flour
Number of subjects: 0
Study 17970229 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) for sensitization to oat, barley, and rye flour
Number of subjects: 0
Study 17970229 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of atopy with specific sensitization
Number of subjects: 0
Study 17970229 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of specific sensitization with age, sex, working hours, working years, smoking status, and pack/years
Number of subjects: 0
Study 16232370 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII (Continuous Subcutaneous Insulin Infusion) in group CSII-1
Number of subjects: 90
Study 16232370 — intervention group
Group type: COMPARATOR
Intervention: Multiple Injections (MI) in group MI-1
Number of subjects: 90
Study 16232370 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII in group CSII-2
Number of subjects: 90
Study 16232370 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CSII-1 vs. MI-1 and CSII-2
Number of subjects: 90
Study 12198064 — intervention group
Group type: COMPARATOR
Intervention: saline (Group 1; n = 13)
Number of subjects: 39
Study 12198064 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.5% (Group 2; n = 13)
Number of subjects: 39
Study 12198064 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.5% plus clonidine 7.5 microg/mL (Group 3; n = 13)
Number of subjects: 39
Study 12198064 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.5% (Group 2)
Number of subjects: 39
Study 12198064 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.5% plus clonidine 7.5 microg/mL (Group 3)
Number of subjects: 39
Study 10438346 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg 2x/day)
Number of subjects: 1790
Study 10438346 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg 2x/day) plus loviride (100 mg 3x/day)
Number of subjects: 1790
Study 10438346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1790
Study 10438346 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine arms
Number of subjects: 1790
Study 7784415 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg for 8 days)
Number of subjects: 20
Study 7784415 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 8 days)
Number of subjects: 20
Study 2184659 — intervention group
Group type: EXPERIMENTAL
Intervention: Valine, isoleucine, and leucine mixture
Number of subjects: 16
Study 2184659 — intervention group
Group type: COMPARATOR
Intervention: Control mixture
Number of subjects: 16
Study 7294077 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (betamethasone)
Number of subjects: 160
Study 7294077 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (EM group)
Number of subjects: 160
Study 29787472 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06372865
Number of subjects: 222
Study 29787472 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 222
Study 29787472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 27102506 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA regimen with potassium canrenoate (200 mg IV bolus) followed by spironolactone (25 mg once daily for 6 months)
Number of subjects: 1603
Study 27102506 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 1603
Study 27102506 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA regimen
Number of subjects: 1603
Study 23981186 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy with a bolus calculator
Number of subjects: 27
Study 23981186 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injection therapy
Number of subjects: 27
Study 21633878 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis center characteristics (dieticians' fulltime-equivalent, type of dialysis center)
Number of subjects: 570
Study 20091042 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation
Number of subjects: 135
Study 18450408 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational support
Number of subjects: 71
Study 18450408 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 71
Study 18450408 — intervention group
Group type: COMPARATOR
Intervention: Paternalism
Number of subjects: 71
Study 18450408 — intervention group
Group type: COMPARATOR
Intervention: Clarification
Number of subjects: 71
Study 18450408 — intervention group
Group type: COMPARATOR
Intervention: Participation
Number of subjects: 71
Study 16167290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% sodium naproxen, administered three times a day for 14 days
Number of subjects: 328
Study 16167290 — intervention group
Group type: COMPARATOR
Intervention: 0.1% diclofenac, administered three times a day for 14 days
Number of subjects: 328
Study 12868207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic vibration applied to the top of each post for thirty minutes
Number of subjects: 60
Study 12868207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic vibration
Number of subjects: 60
Study 10919419 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hand
Number of subjects: 20
Study 10919419 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hand
Number of subjects: 20
Study 9384465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 48-6791 (0.1-0.3-1 mg and 1-2-3 mg doses)
Number of subjects: 10
Study 9384465 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.1 mg kg(-1))
Number of subjects: 10
Study 1472793 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK treatment
Number of subjects: 228
Study 1472793 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 228
Study 6610736 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D vaccine (20 micrograms, two injections separated by one month)
Number of subjects: 0
Study 6610736 — intervention group
Group type: COMPARATOR
Intervention: PRP vaccine (20 micrograms, single injection)
Number of subjects: 0
Study 6610736 — intervention group
Group type: COMPARATOR
Intervention: PRP-D vaccine and PRP vaccine
Number of subjects: 0
Study 30734018 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (standard care plus twice-weekly high-intensity aerobic exercise and resistance training)
Number of subjects: 0
Study 30734018 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 30734018 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 0
Study 30734018 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29063313 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 168
Study 26582269 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation counseling
Number of subjects: 637
Study 26582269 — intervention group
Group type: COMPARATOR
Intervention: Preparation nicotine patch
Number of subjects: 637
Study 26582269 — intervention group
Group type: COMPARATOR
Intervention: Preparation nicotine gum
Number of subjects: 637
Study 26582269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cessation in-person counseling
Number of subjects: 637
Study 26582269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cessation phone counseling
Number of subjects: 637
Study 26582269 — intervention group
Group type: COMPARATOR
Intervention: 16 weeks of combination nicotine replacement therapy (nicotine patch + nicotine gum)
Number of subjects: 637
Study 26582269 — intervention group
Group type: COMPARATOR
Intervention: 8 weeks of combination nicotine replacement therapy (nicotine patch + nicotine gum)
Number of subjects: 637
Study 24612282 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate 0.1% ointment (MPA), applied once daily with ¼ fingertip unit for 5 days
Number of subjects: 16
Study 24612282 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate 0.1% ointment (MPA)
Number of subjects: 16
Study 22049995 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer-administered CPQ(8-10)
Number of subjects: 180
Study 22049995 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer-administered CPQ(11-14)
Number of subjects: 180
Study 22049995 — intervention group
Group type: COMPARATOR
Intervention: Self-administered CPQ(8-10)
Number of subjects: 180